Oxadiazole inhibitors of leukotriene production

A compound of formula I:

• wherein:
• R1 and R2 together with the carbon atom to which they are attached form a C3-10 carbocyclic ring or a 5-11 membered heterocyclic ring, wherein each carbocycle or heterocycle is optionally independently substituted with one to two groups selected from C1-6 alkyl and halogen;
• R3 is 5-11 membered heteroaryl ring containing one to three heteroatoms selected from nitrogen, oxygen and sulfur, wherein each R3 is optionally independently substituted with one to three groups selected from C1-5 alkyl, C1-5 alkoxy, C1-3 alkylhydroxy, —CN, amino, C1-3 alkylamino and C1-3 dialkylamino;
• R4 is hydrogen, halogen, C1-3 alkyl or nitrile;
• R5 is C1-6 alkyl, C3-10 carbocycle, 5-11 membered heterocycle, aryl, 5-11 membered heteroaryl, —C(O)—R6 or —NR7R8, wherein each R5 is optionally independently substituted with one to three groups selected from R9, R10 and R11;
• R6 is C3-8 heterocycle, amino, C1-3 alkylamino, C1-3 dialkylamino or —NH-5-6 membered heterocycle, each optionally independently substituted with one to three groups selected from R9, R10 and R11;
• R7 and R8 are each independently hydrogen, —S(O)nC1-6alkyl or C1-6 alkyl;
• R9, R10 and R11 are independently selected from
• (a) —H,
• (b) —OH,
• (c) halogen,
• (d) —CN,
• (e) —CF3,
• (f) C1-6alkyl optionally substituted with one to three —OH, —N(R12)(R13), aryl, —O—C1-2 alkyl-aryl, 3-6 membered heterocycle, —C(O)-3-6 membered heterocycle, C1-6alkoxy, —S(O)nC1-6alkyl, —CO2R12, halogen, —CN or —C(O)N(R12)(R13),
• (g) C1-6alkoxy,
• (h) —N(R12)(R13),
• (i) —S(O)nC1-6alkyl,
• (j) —CO2R12,
• (k) —C(O)N(R12)(R13),
• (l) —S(O)2N(R12)(R13),
• (m) a 3-10 membered heterocyclic group optionally substituted with one to three groups selected from —OH, C1-6 alkyl, C1-6alkylhydroxy, C1-6 alkyl-CO2R12, —S(O)nC1-6alkyl, oxo, —C(O)N(R12)(R13), and —CO2R12,
• (n′) oxo,
• (o) —C(O)—C1-3 alkyl,
• (p) —C(O)-3-6 membered heterocycle optionally substituted with one to three groups selected from halogen hydroxy and C1-6alkoxy,
• (q) —OR12,
• (r) 5-11 membered heteroaryl;
• R12 and R13 are each independently selected from —H, —C1-6alkyl, —C(O)—C1-6 alkyl, C3-10 carbocycle and a 3-6 membered heterocyclic group, each of which is optionally independently substituted with one to three —OH, C1-6 alkyl, C1-6alkoxy, —C(O)N(R14)(R15), —S(O)nC1-6alkyl, CN, C3-10 carbocycle, —CO2R14, CF3, 3-6 membered heterocycle, halogen;
• or
• R12 and R13 together with the nitrogen atom to which they are attached form a heterocyclyl ring optionally substituted with one to three —OH, CN, C1-6alkoxy or oxo;
• R14 and R15 are each independently selected from —H and —C1-6alkyl;
• n is 0, 1 or 2;
• or a pharmaceutically acceptable salt thereof.